Search: id:"swepub:oai:gup.ub.gu.se/232487" >
Different human vac...
Different human vaccine adjuvants promote distinct antigenin-dependent immunological signatures tailored to different pathogens
-
Knudsen, N. P. H. (author)
-
Olsen, A. (author)
-
Buonsanti, C. (author)
-
show more...
-
Follmann, F. (author)
-
- Zhang, Yuan (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi,Institute of Biomedicine, Department of Microbiology and Immunology
-
Coler, R. N. (author)
-
Fox, C. B. (author)
-
Meinke, A. (author)
-
Oro, U. D. (author)
-
Casini, D. (author)
-
Bonci, A. (author)
-
Billeskov, R. (author)
-
De Gregorio, E. (author)
-
Rappuoli, R. (author)
-
- Harandi, Ali M, 1968 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi,Institute of Biomedicine, Department of Microbiology and Immunology
-
Andersen, P. (author)
-
Agger, E. M. (author)
-
show less...
-
(creator_code:org_t)
- 2016-01-21
- 2016
- English.
-
In: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 6
- Related links:
-
https://www.nature.c...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The majority of vaccine candidates in clinical development are highly purified proteins and peptides relying on adjuvants to enhance and/or direct immune responses. Despite the acknowledged need for novel adjuvants, there are still very few adjuvants in licensed human vaccines. A vast number of adjuvants have been tested pre-clinically using different experimental conditions, rendering it impossible to directly compare their activity. We performed a head-to-head comparison of five different adjuvants Alum, MF59 (R), GLA-SE, IC31 (R) and CAF01 in mice and combined these with antigens from M. tuberculosis, influenza, and chlamydia to test immune-profiles and efficacy in infection models using standardized protocols. Regardless of antigen, each adjuvant had a unique immunological signature suggesting that the adjuvants have potential for different disease targets. Alum increased antibody titers; MF59 (R) induced strong antibody and IL-5 responses; GLA-SE induced antibodies and Th1; CAF01 showed a mixed Th1/Th17 profile and IC31 (R) induced strong Th1 responses. MF59 (R) and GLA-SE were strong inducers of influenza HI titers while CAF01, GLA-SE and IC31 (R) enhanced protection to TB and chlamydia. Importantly, this is the first extensive attempt to categorize clinical-grade adjuvants based on their immune profiles and protective efficacy to inform a rational development of next generation vaccines for human use.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Keyword
- in-water emulsion
- cd4(+) t-cells
- mycobacterium-tuberculosis infection
- humoral immune-responses
- chlamydia-trachomatis
- influenza vaccine
- subunit vaccine
- protective immunity
- pandemic influenza
- h5n1 vaccine
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Knudsen, N. P. H ...
-
Olsen, A.
-
Buonsanti, C.
-
Follmann, F.
-
Zhang, Yuan
-
Coler, R. N.
-
show more...
-
Fox, C. B.
-
Meinke, A.
-
Oro, U. D.
-
Casini, D.
-
Bonci, A.
-
Billeskov, R.
-
De Gregorio, E.
-
Rappuoli, R.
-
Harandi, Ali M, ...
-
Andersen, P.
-
Agger, E. M.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
- Articles in the publication
-
Scientific Repor ...
- By the university
-
University of Gothenburg